Chemistry & pharmacokinetics
Cagrilintide's once-weekly dosing is not a formulation trick; it is written into the molecule.
The fatty tail that makes it weekly
Cagrilintide's once-weekly dosing is not a formulation trick; it is written into the molecule. A fatty-acid tail lets it cling to blood albumin and circulate for days, while carefully placed substitutions stop the amylin backbone from clumping.
This unit shows that molecular design and follows the drug through the body: how it is absorbed, why it lasts a week, and why steady titration over months is unavoidable.
Key terms
The molecule, module by module
Cagrilintide is a lipidated analog of amylin, the natural 37-amino-acid pancreatic hormone. A pharmacokinetic paper describes it as carrying 84% homology to native human amylin, with several amino-acid substitutions and other chemical alterations made to enhance stability, potency and biological half-life. Its own exact residue count, meaning how many amino-acid building blocks sit in its chain, and its full sequence are not stated in the fetched literature, so treat any specific number for cagrilintide itself as reported, not verified. Three functional modules do the work: the amylin backbone (its main chain) that binds the receptor, the N-terminal end of that chain, which in native amylin is clasped into a ring by a sulfur-to-sulfur bond (a disulfide) between the cysteines at positions 2 and 7, and a C-20 fatty-diacid tail attached through a spacer. A review restates the substitution list as Pro25, Pro28 and Pro29 against fibrils, Tyr37Pro for potency, Asn14Glu against deamination and Val17Arg for solubility, and states that the fatty diacid increases the duration of action by binding to albumin. Whether cagrilintide keeps the native disulfide loop is not stated anywhere in the fetched literature. Click each module to see its job. The discovery paper calls the result a stable, lipidated long-acting amylin analogue.
The design idea is the same fatty-acid-plus-albumin trick used across long-acting peptide drugs. Whatever the exact chemistry, the outcome is what matters here: cagrilintide and semaglutide both end up with weekly pharmacokinetics, and the phase 1b trial found cagrilintide exposure did not affect semaglutide exposure or elimination, which is why they can share a pen. The modular picture also makes the engineering legible: change the backbone to stop clumping, add the tail to last a week.
AdvancedWhy albumin binding extends half-life
Albumin binding is a named half-life-extension strategy across this class: reviews list adding a PEG, a glycosylation or an albumin-binding motif as the ways amylin has been modified to extend its half-life and cut dosing frequency, and one review attributes cagrilintide's prolonged action to its fatty diacid binding albumin. The standard account of why that works is that a peptide bound to the most abundant blood protein behaves as a large, protected complex, slowing renal filtration and enzymatic attack; the fetched sources state the strategy and its effect rather than testing that step-by-step account.